TGFB1 and Hepatic fibrosis: In conclusion, our study indicated that byakangelicin could inhibit the progression of liver fibrosis by inhibiting the activation of hepatic stellate cell via regulating the TGF‐β and PDGF signalling pathway and protecting hepatocytes from apoptosis via regulating the ASK/JNK pathway (Figure 6), which provides ideas for the development of potential drugs and treatment methods of liver fibrosis.